SAN DIEGO, Feb. 19, 2016 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, today announced that
Chief Executive Officer Punit
Dhillon received the honor of being named "2016 Most Admired
CEO" by the San Diego Business Journal in the Small Public Company
category.
Mr. Dhillon, who co-founded OncoSec in 2011, was recognized for
his leadership and contributions to the Company's growth,
achievements, and innovation in the field of cancer immunotherapy.
Over the past year, OncoSec has developed a state-of-the-art
technology platform, fostered an employee culture aligned with the
Company's values, and focused its clinical pipeline to address one
of the greatest challenges in oncology today. OncoSec also
fulfilled a key corporate development goal by listing its common
stock on The NASDAQ Stock Market LLC.
"It's an honor for OncoSec to be recognized by the San Diego
Business Journal and alongside several distinguished leaders who
are making a meaningful impact in our city," said Mr. Dhillon. "I'm
pleased to represent OncoSec on behalf of our entire team and thank
our dedicated employees, investors, and fellow associates who have
supported the Company's mission to deliver safer and more effective
treatments for patients in the fight against cancer."
The San Diego Business Journal's 2016 Most Admired CEO Awards
recognizes local industry leaders' achievements within their
companies and in the community. The winners and finalists are
lauded for demonstrating determination and insight yielding
successes for their organizations. Nominees were judged in the
categories of nonprofit organization, business nonprofit,
education, family-owned business, government agency, privately held
company, and public company.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is
designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as IL-12. In Phase I and II clinical
trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety
profile and evidence of anti-tumor activity in the treatment of
various skin cancers as well as the potential to initiate a
systemic immune response. OncoSec's lead program, ImmunoPulse™
IL-12, is currently in Phase II development for several
indications, including metastatic melanoma, squamous cell carcinoma
of the head and neck, and triple-negative breast cancer. In
addition to ImmunoPulse™ IL-12, the Company is also identifying and
developing new immune-targeting agents for use with the
ImmunoPulse™ platform. For more information, please visit
www.oncosec.com.
Contact
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosecs-punit-dhillon-named-most-admired-ceo-by-san-diego-business-journal-300223049.html
SOURCE OncoSec Medical Incorporated